GleamWall
中文EN

BYSI BeyondSpring Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$1.11M$973,000$1.08M$1.47M$968,000$1.00M$874,000$472,000
SG&A expense$956,000$758,000$1.16M$1.12M$672,000$947,000$1.74M$1.23M
Operating income-$2.06M-$1.73M-$2.23M-$2.60M-$1.64M-$1.95M-$2.61M-$1.70M
Pretax income-$2.06M-$1.65M-$2.16M-$2.49M-$1.62M-$1.86M-$2.56M-$1.82M
Income tax$0$100,000$192,000$22,000$2,000$22,000$20,000-$96,000
Net income$50.79M-$849,000-$2.16M-$2.14M-$1.54M-$1.81M$4.48M-$1.73M
EBITDA-$2.04M-$1.71M-$2.21M-$2.75M-$1.56M-$1.87M-$2.53M-$1.68M
EPS (basic)1.24-0.02-0.05—-0.04-0.040.11—
EPS (diluted)—————-0.10——
Balance sheet
Cash & equivalents$580,000$2.70M$4.04M$2.97M$3.95M$9.54M$6.53M$2.00M
Short-term investments$0$3.83M$3.83M$1.00M$141,000—$2.00M$0
Current assets$1.28M$9.90M$13.50M$20.88M$24.41M$25.71M$31.53M$28.58M
PP&E, net$117,000$138,000$152,000$155,000$184,000$202,000$221,000$239,000
Total assets$19.86M$14.61M$18.41M$25.93M$29.48M$31.04M$37.10M$34.31M
Current liabilities$4.62M$14.19M$12.37M$13.58M$12.89M$11.73M$12.66M$11.01M
Total liabilities$4.62M$50.63M$48.76M$49.92M$49.29M$48.59M$49.77M$48.60M
Shareholders' equity$15.24M-$35.57M-$34.49M-$32.16M-$31.77M-$30.22M-$28.31M-$32.90M
Shares outstanding41.41M41.12M41.12M41.12M41.12M40.32M40.32M40.32M
Cash flow statement
Operating cash flow-$3.60M-$3.77M-$3.28M-$5.50M-$4.19M-$5.87M-$4.20M$982,000
Capital expenditure$2,000$0$0$0$0$0$50,000$27,000
Free cash flow-$3.60M-$3.77M-$3.28M-$5.50M-$4.19M-$5.87M-$4.25M$955,000
Investing cash flow$295,000-$5,000$4.48M-$5.15M-$1.22M$10.85M$6.30M-$9.81M
Financing cash flow$8.33M-$74,000-$4.16M$1.97M$3.00M$0$0$1.84M
Depreciation & amortization$18,000$19,000$19,000-$156,000$81,000$82,000$80,000$20,000
Stock-based compensation$471,000$575,000$461,000$167,000$166,000$145,000$244,000$399,000

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.